Non-Invasive Industry ($OCX, $NAOV, $ECOR...)Stocks: A Spotlight on the 14.4% Average Weekly Gain
The non-invasive sector encompasses manufacturers dedicated to the development of noninvasive biological response-activating devices. Companies like NanoVibronix Inc. are at the forefront, innovating medical products using low-intensity acoustic technology. Meanwhile, OncoCyte Corp. specializes in non-invasive, liquid biopsy diagnostics, paving the way for early cancer detection. Neuronetics Inc. stands out with its non-invasive therapeutic solutions targeting psychiatric and neurological disorders.
Tickers in Industry - $OCX, $NAOV, $ECOR, $STIM, $ANIX
Notable Companies
- NanoVibronix Inc.
- OncoCyte Corp.
- Neuronetics Inc.
Market Capitalization
Within the non-invasive theme, the average market capitalization stands at $45.3M. Valuations among these tickers vary, ranging from a modest $4.3M to a more substantial $112.8M. Anixa Biosciences (ANIX) takes the lead with the highest valuation at $112.8M, while NanoVibronix (NAOV) sits at the lower end with a valuation of $4.3M.
Price Movements: Highs and Lows
The non-invasive sector witnessed an impressive average weekly growth of 14.4%. However, on a broader scale, the monthly and quarterly growth rates were -2.1% and -22.87%, respectively. NanoVibronix (NAOV) emerged as the star performer with a staggering price growth of 49.71%. In contrast, Anixa Biosciences (ANIX) saw a minimal decline of 1.11%.
Key Price Movements:
- electroCore (ECOR, $5.08) faced a significant weekly decline of -15.89% as of 8/16/23.
- electroCore (ECOR, $4.68) enjoyed a weekly gain of +15.84% as of 6/30/23.
- Oncocyte (OCX, $0.22) registered a weekly drop of -17.33% as of 5/24/23.
Volume Analysis
The non-invasive sector experienced a remarkable average weekly volume growth of 639.65%. This trend extends to the monthly timeframe, with a growth of 226.76%, and a quarterly growth of 35.2%.
Noteworthy Volume Movements:
- Neuronetics stock saw a record-breaking daily volume growth of 280% of the 65-Day Volume Moving Average on 8/15/23.
- Anixa Biosciences stock experienced a significant daily volume growth of 586% of the 65-Day Volume Moving Average on 7/12/23.
- Oncocyte stock registered a daily volume growth of 437% of the 65-Day Volume Moving Average on 4/11/23.
Fundamental Analysis Ratings
The fundamental analysis ratings provide insights into the industry's health and potential. While specific ratings were not provided, it's essential to note that a rating closer to 1 indicates a more favorable outlook, while a rating closer to 100 suggests challenges or concerns.
In conclusion, the non-invasive sector's recent performance, especially the 14.4% average weekly gain, highlights its potential and the innovative strides being made by companies within this theme.
OCX - On August 25, 2023, OCX's Aroon Indicator showcased a bearish trend. Tickeron's A.I.dvisor detected a scenario where the AroonDown line surpassed 70, while the AroonUp line lingered below 30 for three consecutive days. Historically, such a pattern often precedes a significant decline in the stock. Investors might consider offloading their shares or exploring put options. Past data reveals that in 249 out of 264 instances where OCX exhibited this pattern, the stock trended downwards, suggesting a 90% probability of a similar outcome this time.
STIM - As of August 23, 2023, STIM has registered a -2.44% decline, marking its third consecutive day of descent. Historically, such a three-day downward trajectory often signals further potential drops. Analyzing past patterns, in 297 out of 325 instances where STIM faced a similar three-day decline, the stock continued its downward trend in the subsequent month. This indicates a 90% likelihood of the trend persisting. Investors should monitor STIM closely in the coming weeks.
ANIX - On August 7, 2023, ANIX's Moving Average Convergence Divergence (MACD) Histogram shifted into negative territory, signaling potential bearish momentum for the stock. Historical analysis by Tickeron's A.I.dvisor reveals that in 40 out of 44 previous occurrences where the MACD turned negative, ANIX experienced a subsequent decline. This suggests a 90% probability of the stock continuing its downward trajectory in the upcoming days. Investors should remain vigilant.
OCX in -6.33% downward trend, declining for three consecutive days on January 07, 2025
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where OCX declined for three days, in of 313 cases, the price declined further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
Bullish Trend Analysis
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.658) is normal, around the industry mean (23.476). P/E Ratio (4.558) is within average values for comparable stocks, (83.627). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (14.451) is also within normal values, averaging (41.270).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. OCX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OCX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a developer of ovel, non-invasive, liquid biopsy diagnostics for the early detection of cancer
Industry MedicalSpecialties